[go: up one dir, main page]

CO5630029A2 - Derivados de indol e indolina sustituidos - Google Patents

Derivados de indol e indolina sustituidos

Info

Publication number
CO5630029A2
CO5630029A2 CO05118919A CO05118919A CO5630029A2 CO 5630029 A2 CO5630029 A2 CO 5630029A2 CO 05118919 A CO05118919 A CO 05118919A CO 05118919 A CO05118919 A CO 05118919A CO 5630029 A2 CO5630029 A2 CO 5630029A2
Authority
CO
Colombia
Prior art keywords
ilo
cycloalkyl
alkyl
cycloalk
cyano
Prior art date
Application number
CO05118919A
Other languages
English (en)
Inventor
Nikolay Khanzhin
Mario Rottlander
William Patrick Watson
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of CO5630029A2 publication Critical patent/CO5630029A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

1.- Un derivado de indol o indolina sustituido de fórmula general I en el cual la linea punteada representa un enlace opcional;R1 y R1AND#39 se seleccionan en forma independiente del grupo formado por hidrógeno, alqu(en/in)ilo C1-6, cicloalqu(en)ilo C3-8, cicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6, hidroxi-alqu(en/in)ilo C1-6, hidroxi-cicloalqu(en)ilo C3-8, hidroxi-cicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6, halo-alqu(en/in)ilo C1-6, halo-cicloalqu(en)ilo C3-8, halo-cicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6, ciano-alqu(en/in)ilo C1-6, ciano-cicloalqu(en)ilo C3-8 y ciano-cicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6; o R1 y R1´ junto con el átomo de carbono al cual están unidos forman un anillo saturado o insaturado de 3-8 miembros que contiene, en forma opcional, 1 o 2 heteroátomos;S es 0 o 1;U es O, NR11, S, SO2, SO2NR11, CO-O o CO-NR11; en los cuales R11 se selecciona del grupo formado por hidrógeno, alqu(en/in)ilo C1-6, cicloalqu(en)ilo C3-8, cicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6; o R2 y R11 junto con el átomo de nitrógeno al cual están unidos forman un anillo saturado o insaturado de 4-8 miembros que contiene, en forma opcional, 1, 2 o 3 heteroátomos adicionales;R2 se selecciona del grupo formado por hidrógeno, alqu(en/in)ilo C1-6, cicloalqu(en)ilo C3-8, cicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6, Ar, Ar-alqu(en/in)ilo C1-6, Ar-cicloalqu(en)ilo C3-8, Ar-cicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6, acilo, hidroxialqu(en/in)ilo C1-6, hidroxi-cicloalqu(en)ilo C3-8, hidroxicicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6, halógeno, haloalqu(en/in)ilo C1-6, halo-cicloalqu(en)ilo C3-8, halocicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6, ciano, cianoalqu(en/in)ilo C1-6, ciano-cicloalqu(en)ilo C3-8, cianocicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6, -NO2, NR10R10AND#39-alqu(en/in)ilo C1-6, NR10R10AND#39-cicloalqu(en)ilo C3-8 y NR10R10AND#39-cicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6; en los cuales R10 y R10AND#39 se seleccionan en forma independiente del grupo formado por hidrógeno, alqu(en/in)ilo C1-6, cicloalqu(en)ilo C3-8, cicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6, hidroxi-alqu(en/in)ilo C1-6, hidroxi-cicloalqu(en)ilo C3-8, hidroxicicloalqu(en)ilo C3-8-alqu(en/in)ilo C1-6, ...
CO05118919A 2003-04-25 2005-11-23 Derivados de indol e indolina sustituidos CO5630029A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46538703P 2003-04-25 2003-04-25
DKPA200300631 2003-04-25

Publications (1)

Publication Number Publication Date
CO5630029A2 true CO5630029A2 (es) 2006-04-28

Family

ID=33420358

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05118919A CO5630029A2 (es) 2003-04-25 2005-11-23 Derivados de indol e indolina sustituidos

Country Status (8)

Country Link
US (1) US20060264496A1 (es)
EP (1) EP1631546A1 (es)
JP (1) JP2006524641A (es)
AU (1) AU2004233941A1 (es)
CO (1) CO5630029A2 (es)
MX (1) MXPA05010174A (es)
NO (1) NO20055562L (es)
WO (1) WO2004096767A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS20050127A (sr) * 2002-07-17 2007-06-04 Kyoto Pharmaceutical Industries Ltd., Nova jedinjenja indolina i njihova primena u medicini
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US20050089559A1 (en) 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
JP2007518816A (ja) * 2004-01-23 2007-07-12 アムジエン・インコーポレーテツド バニロイド受容体リガンド及び炎症性及び神経因性疼痛の治療におけるこれらの使用
MX2008002117A (es) 2005-08-17 2008-09-26 Wyeth Corp Indoles sustituidos y metodos de uso de estos.
NZ569517A (en) 2006-02-07 2011-07-29 Lundbeck & Co As H Use of KCNQ-openers for threating or reducing the symptoms of schizophrenia
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
CA2661462C (en) 2006-08-23 2015-09-29 Valeant Pharmaceuticals International Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
ES2375417T3 (es) * 2006-11-28 2012-02-29 Valeant Pharmaceuticals International Análogos 1,4-diamino bicíclicos de retigabina como moduladores de los canales de potasio.
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
CA2694887A1 (en) * 2007-08-01 2009-02-05 Henriette Husum Bak-Jensen Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
US20090076275A1 (en) * 2007-09-19 2009-03-19 David Robert Bolin Diacylglycerol acyltransferase inhibitors
EA025824B1 (ru) * 2009-07-27 2017-02-28 Джилид Сайэнс, Инк. Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
ES2529119T3 (es) 2010-07-02 2015-02-17 Gilead Sciences, Inc. Compuestos heterocíclicos condensados como moduladores de canales iónicos
KR20140033377A (ko) 2011-05-10 2014-03-18 길리애드 사이언시즈, 인코포레이티드 나트륨 채널 조절제로서의 융합된 헤테로시클릭 화합물
NO3175985T3 (es) 2011-07-01 2018-04-28
TW201837023A (zh) 2011-07-01 2018-10-16 美商基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
EP2736330A4 (en) * 2011-07-29 2015-05-27 Tempero Pharmaceuticals Inc COMPOUNDS AND METHODS
WO2013159095A1 (en) * 2012-04-20 2013-10-24 Anderson Gaweco Ror modulators and their uses
CN103508960B (zh) * 2012-06-29 2017-12-12 江苏先声药业有限公司 苯并杂环衍生物
CN112010808B (zh) * 2019-05-31 2021-11-30 上海挚盟医药科技有限公司 作为钾通道调节剂的四氢-1h-苯氮杂卓类化合物及其制备和应用
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
GEAP202415942A (en) 2019-11-08 2024-10-28 Xenon Pharmaceuticals Inc Methods of treating depressive disorders
CN116847843A (zh) 2021-02-09 2023-10-03 泽农医药公司 用于治疗快感缺乏的电压门控的钾通道开放剂
WO2024099269A1 (zh) * 2022-11-11 2024-05-16 华东师范大学 芳基酰胺化合物、包含其的药物组合物及其用途
EP4676912A2 (en) * 2023-03-24 2026-01-14 Purdue Research Foundation Compounds, compositions, and method of inhibiting tau protein and alpha-synuclein aggregation
AU2024268154A1 (en) * 2023-05-09 2025-11-13 Angelini Pharma S.P.A. Novel carboxamide derivatives

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234942A (en) * 1984-10-19 1993-08-10 Ici Americas Inc. Heterocyclic amides and leucotriene antagonistic use thereof
DE4200259A1 (de) * 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
WO1996023783A1 (en) * 1995-02-02 1996-08-08 Smithkline Beecham Plc Indole derivatives as 5-ht receptor antagonist
DE19539861A1 (de) * 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
AR016817A1 (es) * 1997-08-14 2001-08-01 Smithkline Beecham Plc Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento
GB9915414D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
GB9919411D0 (en) * 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
US6117900A (en) * 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
US6348486B1 (en) * 2000-10-17 2002-02-19 American Home Products Corporation Methods for modulating bladder function
US6589986B2 (en) * 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
JP2004531483A (ja) * 2001-02-20 2004-10-14 ブリストル−マイヤーズ　スクイブ　カンパニー Ｋｃｎｑカリウムチャネルのモジュレーターとしてのフルオロオキシンドール誘導体
TWI239942B (en) * 2001-06-11 2005-09-21 Dainippon Pharmaceutical Co N-arylphenylacetamide derivative and pharmaceutical composition containing the same
KR100810468B1 (ko) * 2001-10-10 2008-03-07 씨제이제일제당 (주) 사이클로옥시게나제-2의 저해제로서 선택성이 뛰어난1ｈ-인돌 유도체

Also Published As

Publication number Publication date
US20060264496A1 (en) 2006-11-23
JP2006524641A (ja) 2006-11-02
EP1631546A1 (en) 2006-03-08
AU2004233941A1 (en) 2004-11-11
NO20055562L (no) 2005-11-24
WO2004096767A1 (en) 2004-11-11
MXPA05010174A (es) 2005-11-08

Similar Documents

Publication Publication Date Title
CO5630029A2 (es) Derivados de indol e indolina sustituidos
AR040030A1 (es) Moduladores biciclicos de la funcion del receptor de androgeno
AR049951A1 (es) Derivados de ftalazina como inhibidores de parp
AR054081A1 (es) Derivados de pirimidina, procesos de obtencion y composiciones farmaceuticas
SV2009003258A (es) Nuevos derivados aminopirimidina como inhibidores de plk1
BRPI0414817A (pt) derivados de ácido indol substituìdos e seu uso como inibidores de pai-l
AR058198A1 (es) Derivados de morfolina y composiciones farmaceuticas
CO6290657A2 (es) Derivados polisustituidos de 2-aril-6-fenil-imidazo[1,2-alfa]piridinas su preparacion y su aplicacion en terapeutica
CO6140033A2 (es) Amino-imidazoles y su uso como medicamento para tratar discapacidad coognotiva enfermedad de alzheimer neurodegeneracion y demencia
AR049646A1 (es) Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
CL2021000296A1 (es) Inhibidores tipo indol y azaindol de enzimas pad.
AR063128A1 (es) Compuestos de aril - indol sustituido y sus usos metabolitosde tipo quinurenina / quinurenina como agentes terapeuticos
TW200640916A (en) (1,5-diphenyl-1H-pyrazol-3-yl)oxadiazole derivatives, their preparation and their application in therapeutics
DOP2007000067A (es) Derivados de aminometilpiridina, su preparación y su aplicación en terapéutica
CO2025002028A2 (es) Derivados novedosos de indol sulfonamida 7 sustituidos
GT200700084A (es) Derivados de indanil-piperazinas, su procedimiento de preparación y las composiciones farmaceuticas que los contienen.
CO2025002033A2 (es) Derivados novedosos de indol sulfonamida 7 sustituidos
CO6220956A2 (es) Derivados de pirazolona como inhibidores de pde4
AR039122A1 (es) Derivados de ftalimido como inhibidores de monoamino oxidasa b
ES2177275T3 (es) Derivados de oxadiazolina y su uso como insecticidas.
ECSP078009A (es) Derivados del 4,5-diarilpirrol, su preparación y su aplicación en terapéutica
AR075245A1 (es) Derivados de fenilimidazol utiles en el tratamiento de la hiperlipidemia y obesidad, y composiciones farmaceuticas que los contienen.
AR074915A1 (es) Derivados de 2-piridin-2-il-pirazol-3(2h)-ona, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento de trastornos del aparato cardiovascular, glaucoma y otras patologias.
AR041080A1 (es) Compuestos de 5- croman- 5- il- etilamina substituidos y su uso para el tratamiento de glaucoma
PE20060163A1 (es) Derivados fenilaminopropanol heterociclicos como moduladores de la reabsorcion de monoaminas

Legal Events

Date Code Title Description
FC Application refused